Standard Therapeutic DLI

Phase 1Biologic

UUniversity of Arizona

Standard Therapeutic DLI is one of 3 biologic programs targeting Acute Lymphoid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoid LeukemiaNot yet recruiting

Acute Lymphoid LeukemiaPhase 1

Not yet recruiting

Competition

Competitive Landscape

9 competitors in Acute Lymphoid Leukemia

#DrugCompanyPhaseTrials

Besponsa

WWyeth-Lederle Vaccines

Phase 2

1 2

Maintenance

SSWOG Cancer Research Network

Phase 2

1 3

Standard Therapeutic DLI

UUniversity of Arizona

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Not yet recruiting

Acute Lymphoid Leukemia

NCT07254793

Clinical

Trials by Indication[1]

Pain1 trial

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

Completed·UUniversity of Arizona·Phase 4·NCT00251732·150 enrolled

Acute Lymphoid Leukemia1 trial

A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent or Treat Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation

Not yet recruiting·UUniversity of Arizona·Phase 1·NCT07254793·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard Therapeutic DLI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard Therapeutic DLI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard Therapeutic DLI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Arizona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Arizona

Standard Therapeutic DLI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Pain1 trial

Acute Lymphoid Leukemia1 trial

References

Drug Info

Quick Facts

Related News